Alternatively, CAR-NK cells targeting markers of dormancy represent a potential therapeutic tool by either complementing the adaptive anti-tumor response of cytotoxic CD8+ cells or by offering an alternative for cancers unresponsive to T-cell-based therapies. The gene discussed is CD8A; the disease is neoplasm.